These findings differed from the results of the IMpassion 130 trial, which showed the benefit of atezolizumab only held in patients with PD-L1 positive metastatic TNBC defined as the expression on tumor-infiltrating immune cells ≥ 1% by SP142 assay. This evidence concerns the gene CD274 and neoplasm.